Amyloidosis Treatment Market Size, Share & Trends Analysis Report, 2026-2034
REPORT DETAILS
Amyloidosis Treatment Market Summary and Key Insights
The amyloidosis treatment market size was valued at USD 6.03 billion in 2025. The market is projected to grow at a CAGR of 7.23% from 2026 to 2034. Rise in targeted therapies and an expanding aging population susceptible to the wild-type disease are a few of the key factors driving market growth.
Market Statistics
Amyloidosis Treatment Market Key Takeaways
- North America held the largest revenue share of 42.7% in 2025. This is due to the rising aging population in the region.
- Asia Pacific is expected to register a significant CAGR of 8.9%. The increasing prevalence of chronic diseases is driving the regional market growth.
- The Chemotherapy segment dominated with a 46.5% share in 2025. This is owing to its established efficacy in managing related conditions.
- The Transplantation segment is expected to grow at a 10.8% CAGR. The rising recognition of hematopoietic stem cell transplantation as a curative option for patients suffering from AL amyloidosis drives the segment’s growth.
- The Hospitals & Clinics segment accounted for a major market share of 61.4% in 2025. The comprehensive infrastructure of these end users contributes to the segment’s leading position.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations.
Industry Dynamics
- Improved diagnostic tools, such as advanced imaging techniques and enhanced biomarker tests, have enabled earlier and more accurate identification of amyloidosis.
- The proliferation of clinical trials has raised awareness about amyloidosis among healthcare professionals and the public. This, in turn, has resulted in increased interest in amyloidosis therapies.
- The shift towards gene-silencing therapies is expected to create several market opportunities.
- High amyloidosis therapy costs may present market challenges.
AI Impact on Amyloidosis Treatment Market
- AI facilitates amyloidosis research through the analysis of clinical, genetic, and biomarker data, thus providing possible solutions for treatment.
- It allows for early diagnosis and personalized therapy through disease progression predictions and patient reaction to treatments.
- AI is able to increase the effectiveness of clinical trials through more effective patient selection, data analysis, and monitoring of adverse events.
- It provides more effective treatment plans and patient monitoring through predictive analytics
Amyloidosis Treatment Market in Simple Terms
Amyloidosis therapies involve medications that assist in preventing and halting the deposition of amyloid proteins within the organs and tissues of the body. Therapies for amyloidosis depend on the specific type of amyloidosis disease, but the treatment methods can involve targeted amyloidosis medications, chemotherapy, supportive therapy, or even stem cell transplants. The aim of treatment is to reduce the protein deposits and improve the patient’s quality of life.
Amyloidosis is a rare but serious condition characterized by the abnormal accumulation of amyloid proteins in various organs leads to organ dysfunction. The treatment for amyloidosis has evolved significantly, with approaches tailored to the specific type of amyloidosis diagnosed. AL amyloidosis, AA amyloidosis, and transthyretin amyloidosis are a few types of amyloidosis, and each type requires different therapeutic methods.
The rising geriatric population is driving the amyloidosis treatment market. As per data published by the United Nations, the number of people aged 65 years and above worldwide is projected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. Older adults often have multiple comorbidities, which complicate their health and increase the likelihood of conditions such as amyloidosis. This necessitates more comprehensive diagnosis and treatment options.
Source: Polaris Market Research Analysis
For Specific Research Requirements: Download Sample Report
The amyloidosis treatment market is driven by the increasing number of patients having genetic mutations in blood cell DNA. Certain genetic mutations, including those associated with hereditary forms of amyloidosis such as ATTR amyloidosis, predispose individuals to develop the amyloidosis condition, leading to a higher incidence of diagnosed cases. This increases the demand for amyloidosis treatments.
How Amyloidosis Treatment Works?
Disease Diagnosis and Evaluation: Physicians will initially identify the type of amyloidosis and the affected organs based on blood tests, imaging tests, biopsies, among others.
Treatment Determination: From the diagnosis results, doctors can determine what the best treatment for the condition is, whether it may be targeted drugs, chemotherapy, immunotherapy, support therapy, or bone marrow transplant.
Reduction of Abnormal Protein Depositions: Medication works by preventing and reducing abnormal protein depositions within the body.
Treatment of Symptoms and Functions of Organs: Other medications might also involve treating symptoms, enhancing functions of the heart, kidneys, nervous system, liver, and other organ systems involved in the deposition of the amyloid.
Monitoring: Patients will be constantly monitored through lab and clinical tests.
Amyloidosis Treatment Market Driver Analysis
Advancements in Diagnostic Technologies
Improved diagnostic tools, such as advanced imaging techniques and enhanced biomarker tests, allow for earlier and more accurate identification of amyloidosis. This leads to timely treatment initiation, increasing the overall demand for amyloidosis therapies. Moreover, enhanced diagnostics enable the differentiation between various subtypes of amyloidosis, such as AL and ATTR, which guide effective treatment decisions and create a demand for tailored therapies. Therefore, advancements in diagnostic technologies drive the amyloidosis treatments market growth.
Increasing Clinical Trials Worldwide
The proliferation of clinical trials raises awareness about amyloidosis among healthcare professionals and the public. This increases interest in amyloidosis therapies as patients seek options that are potentially more effective. Additionally, a growing number of clinical trials led to the establishment of dedicated research centers and networks specializing in amyloidosis, which enhances the overall treatment environment and increases patient engagement. Therefore, the rising number of clinical trials worldwide fuels the growth of the global amyloidosis treatment market.
Role of Precision Medicine in Amyloidosis Treatment
The use of precision medicine is gaining momentum in the management of amyloidosis since it enables medical professionals to prescribe treatments depending on the type of the disease and individual health characteristics of patients. Advanced diagnostics, genetic testing, and biomarkers enable the identification of abnormal proteins that cause amyloidosis and the selection of appropriate treatment options. Research in this field is expected to enhance the quality of treatment for patients with amyloidosis.
Rise of Emerging Therapies
New therapies are providing more options for the management of amyloidosis owing to their precision and efficiency to slow down the progression of the disease. Therapies that prevent the formation of abnormal proteins, stabilize the protein before the accumulation into deposits, and get rid of any existing amyloid deposits from organs are under development. These include gene silencing therapy and monoclonal antibodies that have had much success in the clinical testing for the management of amyloidosis. With these drugs getting approvals from regulatory authorities, they are expected to give patients better chances of survival and enable the maintenance of organ function.
Source: Polaris Market Research Analysis
Cost and Accessibility
The issue of costs associated with treatment and accessibility of the therapy is one of the significant problems related to amyloidosis treatment since the most modern amyloidosis drugs are quite costly and cannot be obtained everywhere. The availability of treatment for this condition usually depends on several factors such as the healthcare system, insurance and reimbursement, and other things. While the development of targeted therapies is an obvious improvement that enables more effective patient treatment, their cost remains high. In the near future, initiatives geared towards providing insurance coverage, increasing awareness, developing cheaper treatments, and increasing access to healthcare services will ensure that amyloidosis treatment becomes more available.
Amyloidosis Treatment Market Segment Insights
Amyloidosis Treatment Market Breakdown, By Treatment
Based on treatment, the global amyloidosis treatment market is segmented into chemotherapy, immunosuppressive drugs, transplantation, supportive care, surgery, and others. The chemotherapy segment dominated the market in 2023 due to its established efficacy in managing related conditions, particularly AL amyloidosis. Chemotherapy agents, such as bortezomib and cyclophosphamide, have shown significant success in reducing the production of amyloid light chains, which are responsible for the disease's progression. The ability of these drugs to achieve rapid hematologic responses has solidified their position as a first-line treatment, driving substantial market growth. Furthermore, the increasing prevalence of AL amyloidosis, coupled with advancements in combination therapies, has propelled the demand for chemotherapy as clinicians seek effective ways to enhance patient outcomes and prolong survival rates.
The transplantation segment is expected to grow at a robust pace in the coming years, owing to the rising recognition of hematopoietic stem cell transplantation as a curative option for patients suffering from AL amyloidosis. Healthcare providers are increasingly considering transplantation for patients affected by advanced disease as more clinical studies demonstrate the long-term benefits and improved survival rates associated with this approach. Additionally, the development of better pre-and post-transplant care protocols has improved patient outcomes and reduced complications, further encouraging the adoption of transplantation. The growing body of evidence supporting its effectiveness is likely to stimulate demand in the coming years, positioning transplantation as a pivotal treatment modality in the management of amyloidosis.
Amyloidosis Treatment Types Compared
| Type of Treatment | Treatment Intention | Use Of The Treatment | Major Advantage |
| Targeted Therapies | Prevent or slow down abnormal protein production | ATTR Amyloidosis | Slows disease progression |
| Chemotherapy | Lowers abnormal plasma cells | AL Amyloidosis | Lowers amyloid protein production |
| Immunotherapy | Target specific proteins | Selected types of amyloidosis | Better efficacy of treatment |
| Stem Cell Transplantation | Replace abnormal blood cells | Eligible patients of AL amyloidosis | Lowers disease progression |
| Supportive Treatments | Control symptoms and protect vital organs | All types of amyloidosis | Improves quality of life |
| Combined Therapy | The use of multiple therapies | Complex types of amyloidosis | Lowers disease progression |
Source: Polaris Market Research Analysis
Amyloidosis Treatment Market Breakdown By End User
In terms of end user, the global amyloidosis treatment market is categorized into hospitals & clinics, ambulatory surgical centers, home care settings, and others. The hospitals & clinics segment accounted for a major market share in 2023 due to their comprehensive infrastructure and specialized medical staff equipped to handle complex cases of amyloidosis. These facilities provide a multidisciplinary approach, allowing for collaboration among oncologists, hematologists, and nephrologists to deliver optimal care. The availability of advanced diagnostic tools and treatment options in hospitals and clinics further enhances patient outcomes, attracting more individuals seeking timely and effective interventions. Additionally, the increasing complexity of treatment protocols and the need for close monitoring during chemotherapy and other therapies have set the role of these institutions as primary treatment centers.
The home care settings segment is projected to grow at a rapid pace during the forecast period owing to the rising preference for patient-centered care, where individuals receive treatment in the comfort of their own homes. Advances in telemedicine and home health monitoring technology enable healthcare providers to deliver quality care remotely, facilitating ongoing support and treatment adherence. Moreover, as more patients affected by amyloidosis achieve stability or remission, they often prefer less invasive and more convenient treatment options, further driving demand for home care solutions. The increasing focus on reducing hospital readmissions and healthcare costs also encourages the shift toward home care, making it a vital segment in the evolving landscape of care delivery for amyloidosis.
Use Cases of Amyloidosis Treatment
| Application | Purpose |
| Light chain amyloidosis treatment | Lowers light chain proteins production and slows down progression of the disease |
| ATTR amyloidosis treatment | Supports stabilization of the transthyretin protein and prevents formation of new amyloids |
| Treatment of cardiac amyloidosis | Maintains function of the heart and reduces heart failure symptoms |
| Management of kidney diseases | Protects the kidneys from harm due to amyloid formation |
| Nerve pain treatment | Improves symptoms such as pain, numbness, and weakness |
| Stem cell transplantation | Treatment chosen for certain patients for better results |
| Supportive care | Alleviates symptoms experienced during the treatment process |
Source: Polaris Market Research Analysis
Source: Polaris Market Research Analysis
Regulatory Landscape
The regulatory environment for amyloidosis treatments is changing as regulatory bodies make efforts to increase the availability of rare disease treatments. Regulatory bodies must be convinced of a drug's safety, efficacy, and quality by conducting clinical trials before licensing it. Orphan drug programs and expedited reviews are two other strategies that encourage the manufacture of rare disease drugs, including those treating amyloidosis. Post-approval, there are regulations in place to ensure that the medications maintain their efficacy and safety.
Amyloidosis Treatment Regional Insights
By region, the study provides the amyloidosis treatment market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the highest revenue share of the global amyloidosis treatment market in 2023 due to the rising aging population, increasing awareness of the disease, and advancements in diagnostic technologies that facilitate earlier detection. Comprehensive healthcare infrastructure, along with access to specialized treatment centers, enhances the quality of care available to patients. Additionally, ongoing research and clinical trials conducted in the US significantly contribute to the development of innovative therapies for amyloidosis, further solidifying the country's leadership in the regional market.
Source: Polaris Market Research Analysis
The Asia Pacific amyloidosis treatment market is expected to register a significant CAGR during the forecast period due to the increasing prevalence of chronic diseases, rising healthcare expenditure, and improving healthcare infrastructure in countries such as China and India. Furthermore, advancements in healthcare technologies and an expanding focus on personalized medicine enhance treatment accessibility and efficacy, making Asia Pacific a key region in the future landscape. Further, a large patient population and significant investments in healthcare resources would fuel the market growth in the region in the coming years.
Amyloidosis Treatment Market – Key Players & Competitive Insights
Major market players are investing heavily in research and development to expand their offerings, which will help the amyloidosis treatment market grow even more. Market participants are also undertaking a variety of strategic activities, including innovative launches, international collaborations, higher investments, and mergers and acquisitions between organizations, to expand their global footprint. To expand and survive in a more competitive and rising market environment, the amyloidosis treatment market players must offer innovative solutions.
The amyloidosis treatment market is fragmented, with the presence of numerous global and regional market players. A few major players in the market include Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.
Pfizer Inc., founded in 1849 by Charles Pfizer and his cousin Charles Erhart in Brooklyn, New York, is a global player in biopharmaceuticals. The company has a rich history spanning over 170 years, marked by innovation and a commitment to improving health outcomes worldwide. Pfizer Inc. has emerged as a major player in the treatment of transthyretin amyloidosis (ATTR), particularly through its innovative therapies, VYNDAQEL (tafamidis) and VYNDAMAX. These medications specifically target transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive disease characterized by the accumulation of misfolded transthyretin proteins in the heart and other organs.
Takeda Pharmaceutical Company Limited, founded in 1781, is a prominent Japanese multinational pharmaceutical company headquartered in Tokyo, Japan. Takeda has made significant strides in this area with the development of therapies aimed at treating transthyretin amyloidosis (ATTR). Moreover, the company has been involved in several clinical trials aimed at evaluating the safety and efficacy of its amyloidosis treatments. In May 2024, Takeda Pharmaceutical signed an agreement to license AC Immune's ACI-24.060, an immunotherapy that targets amyloid beta, a protein that may be a root cause of amyloidosis.
Key Companies in Amyloidosis Treatment Market
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- GSK plc.
- Takeda Pharmaceutical Company Limited
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Merck KGaA
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Ionis Pharmaceuticals
- Bristol-Myers Squibb Company
- Amgen Inc.
Future Outlook
The amyloidosis treatment market is predicted to grow steadily in the coming years due to the continued advancements in disease awareness, diagnostic modalities, and treatments. Continuous efforts to develop novel drugs through research on gene-silencing approaches, monoclonal antibodies, and many other therapeutic strategies are projected to result in the availability of various therapeutic options for different types of amyloidosis. Other factors driving the growth of the market include increasing rare diseases research, advancing precision medicine, and regulatory support. With improved treatment and access to treatment centers, the future prospects of the market look promising.
Amyloidosis Treatment Industry Developments
- June 2026: Attralus, Inc., announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL) amyloidosis.(source: globenewswire.com)
- May 2026: Immix Biopharma, Inc. announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response (CR). The company highlighted that the new NEXICART-2 CR rate is 95% (19 out of 20 patients).(source: immixbio.com)
Amyloidosis Treatment Market Segmentation
By Treatment Outlook (Revenue, USD Billion, 2021–2034)
-
Chemotherapy
- Immunosuppressive Drugs
- Transplantation
- Supportive Care
- Surgery
- Others
By End Use Outlook (Revenue, USD Billion, 2021–2034)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Amyloidosis Treatment Report Scope
| Report Attributes | Details |
| Market Size Value in 2025 | USD 6.03 billion |
| Market Size Value in 2026 | USD 6.45 billion |
| Revenue Forecast by 2034 | USD 11.29 billion |
| CAGR | 7.23 % from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
Source: Polaris Market Research Analysis
Amyloidosis Treatment Market Frequently Asked Questions
The global amyloidosis treatment market size was valued at USD 6.03 billion in 2025 and is projected to grow to USD 11.29 billion by 2034.
The global market is projected to register a CAGR of 7.23 % during 2026–2034
North America held the largest share of the global market in 2025.
A few key players in the market are Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc.; Takeda Pharmaceutical Company Limited; Alnylam Pharmaceuticals, Inc.; Sanofi; Merck KGaA; F. Hoffmann-La Roche Ltd; Novartis AG; Ionis Pharmaceuticals; Bristol-Myers Squibb Company; and Amgen Inc.
The transplantation segment is projected for significant growth in the global market during the forecast period.
The hospitals & clinics segment dominated the amyloidosis treatment market in 2025.
Based on the type and organs involved, various modalities, including targeted therapies, chemotherapies, supportive therapies, stem cell transplants, and new-generation gene-silencing drugs, have been identified to manage the condition effectively.
In case of early diagnosis, treatments can be initiated before there is much damage to vital organs. Early diagnosis will help in more effective treatment, slow disease progression, preserve the functions of the heart, kidneys, and nerves, and enhance the quality of life.
Key market drivers include the growing awareness regarding rare diseases, advancements in diagnostic techniques, and increasing investments in the field of rare diseases.
Download Sample Report of Amyloidosis Treatment Market
Please fill out the form to request a customized copy of the research report.
